Back to top

Viridian Therapeutics (VRDN) Receives a Rating Update from a Top Analyst

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $40.00. According to...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Viridian Therapeutics, Inc. (VRDN)